EGON-ZEHNDER
28.5.2019 07:02:25 CEST | Business Wire | Press release
Egon Zehnder, the world’s leadership consulting firm, has formalized an agreement to purchase a minority stake in Zurich, Switzerland-based Sinequanon (SQN), a firm that uses AI and advanced analytics to improve workplace culture and performance. SQN is the first to have cracked the code linking culture to performance consistently over time and in every client engagement.
The investment in SQN signals Egon Zehnder’s intent to build on its 55 years of experience shaping leadership and culture through SQN’s unique combination of advanced technology and a human approach to leadership. The companies will work together to disseminate SQN’s Living Analytics™ platform and Flow Operating System™.
SQN’s flowOS™ uses a data-driven and AI-enabled process to identify an organization’s optimal culture and then drives the behavioral change needed by individuals, teams and business units. In its work with clients, flowOS™ has consistently delivered significant improvements in people energy and productivity.
“We hear consistently from clients that culture change is one of the most challenging aspects of leadership. In SQN we have found an innovative partner to deliver integrated services to our clients by marrying both human leadership insights and pioneering technology,” said Jill Ader, Chairwoman, Egon Zehnder. “We strongly believe the best consulting services we can offer our clients combine technology and humanity,” she added.
The partnership is founded on the shared belief that culture change is critical to helping organizations adapt to and thrive in today’s complex world. It combines Egon Zehnder’s expertise advising and unlocking the potential of senior leaders with SQN’s ability to assess and accelerate the power of the full organization through cultural change.
“It has always frustrated me that large organizations trap massive amounts of human energy. In fact, our data shows that less than 10% of employees operate at their full potential. Now as organizations are feeling the brutal effect of disruption, an extraordinary win-win opportunity between employees and businesses is emerging. My life’s mission is to find a business-minded method to enable this – and that is flowOS™,” said Per Lagerstrom, Chief Executive Officer, SQN. “Egon Zehnder and SQN share a core mission to unlock human potential. I believe we can make magic together, and am excited to be partnering with them,” he added.
“We believe the world needs more great leaders. In fact, recent research we conducted with 402 CEOs revealed they find culture change one of the most challenging aspects of the role,” noted Gabriel Andrade, Partner, Egon Zehnder and Board member, SQN. “With SQN, the intelligence of the end-to-end operating system and guided support we can provide clients can change human resources and performance management for the foreseeable future.”
SQN brings new capabilities to an already powerful set of partnerships. Egon Zehnder’s strategic alliance with Mobius Executive Leadership, the London and Cambridge, MA-based leadership development firm, delivers customized executive development programs at the CEO and executive levels that enable breakthroughs often described by participants as “life changing,” which in turn can serve as a multiplier to the impact of SQN. In addition, Egon Zehnder has partnered with Paradox Strategies, the consulting firm co-founded by Harvard University Professor Linda Hill, to develop the Innovation Quotient (IQ), a proprietary culture diagnostic based on Hill’s research that helps clients better understand the degree to which their cultures enable – or inhibit – their ability to innovate.
Notes to Editors
Sinequanon (SQN) is a privately held PeopleTech start-up founded in 2015. While we work globally and across industries, our home is in Switzerland with operations in South Africa and the Czech Republic.
SQN has a passionate team of 60, unified by a fundamental belief in our ability as humans to radically change and grow and a hunger to marry the soft skills with the hard. Our people work across behavioral, neural and data science, technology and client services.
At SQN, we believe that human capital management and change consulting are ripe for disruption. We have combined data, science and sound business principles into a ground breaking approach that taps into the well of human energy, so often trapped in large businesses, delivering material improvements to both the employee experience and the company’s bottom line.
We offer a suite of culture change products and services under the Living Analytics™ and flowOS™ brands, coupled with a disruptive tech enabled client delivery model.
About Egon Zehnder
Egon Zehnder is the world’s leadership consulting firm, sharing one goal: to transform people, organizations and the world through great leadership.
We know what great leaders can do and are passionate about delivering the best leadership solutions for our clients.
As One Firm, our more than 480 Consultants in 68 offices and 40 countries bring our individual strengths to form one powerful collaborative team.
We partner closely with public and private corporations, family-owned enterprises, and non-profit and government agencies to provide Board advisory services, CEO search and succession, executive search, executive assessment, leadership development and organizational transformation.
We offer a range of integrated services to support our leadership consulting work: Our strategic alliance with Mobius Executive Leadership, the London and Cambridge, MA based leadership development firm, delivers customized executive development programs at the CEO and executive levels that enable breakthroughs often described by participants as “life changing.” In addition, we have partnered with Paradox Strategies, the consulting firm co-founded by Harvard University Professor Linda Hill, to develop the Innovation Quotient (IQ), a proprietary culture diagnostic based on Hill’s research that helps clients better understand the degree to which their cultures enable – or inhibit – their ability to innovate.
We share a commitment and pride in doing work that contributes to successful careers, stronger companies and a better world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005228/en/
Contact:
Global media Hilary Crnkovich Global Head of Marketing and Communications P: +1 312-260-8978
Stacy Drumtra US Head of Marketing and Communications P: +1 312-260-8974
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release
The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release
Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
